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Reply to E. Hindié and K.R. Hess
Hindié1 has pointed out that the absolute difference in
4-year relapse-free survival (RFS) rates between the
treatment and placebo arms in patients with stage IIIA
disease (7%) was considerably lower compared with
rates in patients with stage IIIB disease (19%) and
stage IIIC disease (16%; all American Joint Commis-
sion on Cancer [AJCC] 7th edition). However, the
hazard ratio (HR) for RFS, which measures the re-
duction in risk regardless of absolute baseline risk, was
consistent across substages. HR for stage IIIA disease
(AJCC 7th edition melanoma staging system) was 0.58,
which represents a 42% reduction in risk, 0.49 for stage
IIIB disease (51% reduction in risk), and 0.46 for stage
IIIC disease (54% reduction in risk). These data dem-
onstrate that the magnitude of the RFS benefit of ad-
juvant dabrafenib and trametinib was consistent across
substages and comparable to the overall treatment ef-
fect observed in the intention-to-treat population.2
Therefore, it cannot be assumed that there would be
a different risk reduction for patients with low-risk stage
IIIA disease (# 1 mm) on the basis of available data;
however, a prospective study is needed to confirm these
findings in patients with stage IIIA melanoma (# 1mm).
As Hindié1 indicates, patients with stage IIIA mela-
noma in the COMBI-AD study had a nodal burden of
greater than 1 mm. Therefore, similar to prespecified
analyses by the AJCC 7th edition melanoma staging
system, post hoc analyses by the AJCC 8th edition
melanoma staging system included patients with
lymph node metastasis of greater than 1 mm.
The adverse event profile in the COMBI-AD trial was
consistent with the approved indications in metastatic
melanoma, non–small-cell lung cancer, and anaplastic
thyroid cancer. Adverse events were reversible and
manageable, as indicated by a median duration of ex-
posure that was close to the planned 12 months of
treatment (11.0 months for dabrafenib plus trametinib
and 10.0 months for placebo3). The most common
adverse event reported was pyrexia, which could be
managed with dose interruptions and supportive
measures—for example, acetaminophen or corticosteroids.
Evaluation of treatment risks and benefits is important
and must be discussed by the physician and patient
before initiating adjuvant treatment, which would in-
clude a discussion of the absolute baseline risk of
recurrence. The effect of relapse of melanoma at any
stage can be devastating, especially in the case of
systemic relapse. In the study cited by Hindié,1 esti-
mated 5-year survival rates after first relapse were
similar in patients with stage IIIA and IIIB disease
(20%). Of note, the type of metastasis—in-transit or
nodal versus systemic—but not melanoma substage
was independently associated with overall survival
after first relapse.4 Therefore, it is important to discuss
adjuvant treatment options with patients with stage IIIA
melanoma (lymph node metastasis . 1 mm).
In reply to Hess,5 our article presents updated efficacy
results with 10 months of additional follow up that
confirms RFS benefit with adjuvant dabrafenib plus
trametinib. The benefit is clearly demonstrated with the
more mature RFS analysis and the cure rate model.
Departure from the proportional hazards assumption
discussed in the letter by Hess5 is not unexpected in
the adjuvant setting in which RFS Kaplan-Meier curves
begin to plateau at a certain point in time, indicating
the presence of a fraction of patients who will likely
never experience disease recurrence and may be
cured. In the COMBI-AD trial, RFS curves become
more or less parallel beyond 3 years and the difference
between curve tails is quantified by the cure ratemodel
estimates. We agree with Hess5 that, in this setting,
RFS HR alone (HR, 0.49) may not show the entire
picture regarding the efficacy of the tested drug versus
control, and this is precisely the rationale for com-
plementing the RFS HR with cure rate estimates
(54% v 37%), as we did in this analysis.
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Recherche Médicale U 1189, Centre Hospitalier
Universitaire Lille, Lille, France
Jacob Schachter, MD, PhD
Sheba Medical Center, Tel HaShomer, Israel, and Tel Aviv
University, Tel Aviv, Israel
Thierry Lesimple, MD, MSc
Centre Eugène Marquis, Rennes, France
Ruth Plummer, MD, PhD
Freeman Hospital and Newcastle University, Newcastle
upon Tyne, United Kingdom
Kohinoor Dasgupta, PhD
Novartis Healthcare, Hyderabad, India
Tomas Haas, PhD
Novartis AG, Basel, Switzerland
Mark Shilkrut, MD, PhD and Eduard Gasal, MD
Novartis Pharmaceuticals, East Hanover, NJ
Richard Kefford, MD, PhD
Melanoma Institute Australia, The University of Sydney,
Macquarie University, and Westmead Hospital, Sydney,
NSW, Australia
John M. Kirkwood, MD
UPMC Hillman Cancer Center, University of Pittsburgh,
Pittsburgh, PA
Axel Hauschild, MD
University Hospital Schleswig-Holstein, Kiel, Germany
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
AND DATA AVAILABILITY STATEMENT
Disclosures provided by the authors and data availability statement (if
applicable) are available with this article at DOI https://doi.org/10.1200/
JCO.19.00004.
ACKNOWLEDGMENT
COMBI-AD was originally sponsored by GlaxoSmithKline; dabrafenib and
trametinib were designated as assets of Novartis on March 2, 2015, after
which Novartis took over sponsorship of the trial. Novartis funded
editorial assistance provided by Michael Demars, PhD (Articulate
Science, LLC).
REFERENCES
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